Granules India Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Granules India will hold a meeting of the Board of Directors of the Company on 29 April 2026.

Granules Conusmer health is a wholly-owned subsidiary of Granules Pharmaceuticals, Inc and step-down subsidiary of the Granules India. It serves as Granules? front-end division for OTC products in the U.S., leveraging Granules India?s manufacturing efficiencies, regulatory compliance, and integrated supply chain.

The FDA inspection was conducted at the company?s packaging facility in Manassas, Virginia, from December 1 to 3, 2025. This marks the facility?s second FDA inspection, following the March 2023 audit, which also concluded with zero observations.

Krishna Prasad Chigurupati, chairman and managing director of Granules India, said, ?Granules Consumer Health plays a critical role in our global operations as a packaging and distribution site. We process controlled substances and over-the-counter (OTC) products across three advanced packaging lines. Achieving zero observations in this inspection reflects the strong culture of quality, safety and regulatory excellence demonstrated by our teams.?

Granules India is primarily involved in the manufacturing and sale of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs). The company reported a 27.73% jump in consolidated net profit to Rs 150.21 crore on 22% increase in revenue from operations to Rs 1,387.94 crore in Q3 FY26 over Q3 FY25.

Powered by Capital Market - Live News

Granules India announced that its US step-down subsidiary, Granules Consumer Health, LLC, a wholly-owned subsidiary of Granules Pharmaceuticals, Inc. has received an Establishment Inspection Report (EIR) with a No Action Indicated (NAI) Status from the US Food and Drug Administration (FDA).

The FDA inspection was conducted at the company's packaging facility in Manassas, Virginia, from December 1 to 3, 2025. This marks the facility's second FDA inspection, following the March 2023 audit, which also concluded with zero observations.

Powered by Capital Market - Live News

Revenue growth during the quarter was driven by Finished Dosages (FD) segment in North America and Europe.

Profit before tax (PBT) jumped 32.36% YoY to Rs 202.23 crore during the quarter.

EBITDA stood at Rs 308.1 crore, registering the growth of 34% compared with Rs 230.3 crore in Q3 FY25. EBITDA margin improved to 22% in Q3 FY26 as against 20% in Q3 FY25.

For Q3 FY26, Finished Dosages, Active Pharmaceutical Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Peptides/CDMO contributed 76%, 11%, 11%, and 2% of revenue from operations, respectively.

Net debt stood at Rs 1,015.1 crore and Net debt to EBITDA at 0.91x in Q3 FY26.

Krishna Prasad Chigurupati, chairman & managing director of Granules India said, ?Q3 has been one of our strongest quarters, reflecting disciplined execution of strategic growth initiatives and we are well positioned for sustained growth momentum. Our strong financial performance, on-going R&D investments, combined with advances in ESG stewardship and our expanding global supply footprint, reinforces our commitment to building a resilient, innovation-led pharmaceutical platform that delivers long-term value for all stakeholders.?

Granules India is primarily involved in the manufacturing and sale of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs).

The scrip declined 1.09% to end at Rs 564.95 on the BSE.

Powered by Capital Market - Live News